ev3 prices IPO (Initial public offering)at $200m, plans Nasdaq listing
This article was originally published in Clinica
ev3, the Plymouth, Minnesota developer of endovascular devices to treat cardiovascular, peripheral vascular and neurovascular diseases, has priced its planned initial public offering. The company intends to sell 11.77 million shares at $16-18 per share, and list on Nasdaq. Assuming a mid-point price of $17 per share, the company will raise $200m, or $182m net of expenses and underwriting discounts.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.